Discovery reveals blocking inflammation may lead to chronic pain

Women and pain


Using anti-inflammatory drugs and steroids to relieve pain could increase the chances of developing chronic pain, according to researchers from McGill University and colleagues in Italy. Their research puts into question conventional practices used to alleviate pain. Normal recovery from a painful injury involves inflammation and blocking that inflammation with drugs could lead to harder-to-treat pain.

“For many decades it’s been standard medical practice to treat pain with anti-inflammatory drugs. But we found that this short-term fix could lead to longer-term problems,” says Jeffrey Mogil, a Professor in the Department of Psychology at McGill University and E. P. Taylor Chair in Pain Studies.

The difference between people who get better and don’t

In the study published in Science Translational Medicine, the researchers examined the mechanisms of pain in both humans and mice. They found that neutrophils – a type of white blood cell that helps the body fight infection – play a key role in resolving pain.

“In analyzing the genes of people suffering from lower back pain, we observed active changes in genes over time in people whose pain went away. Changes in the blood cells and their activity seemed to be the most important factor, especially in cells called neutrophils,” says Luda Diatchenko a Professor in the Faculty of Medicine, Faculty of Dentistry, and Canada Excellence Research Chair in Human Pain Genetics.

Inflammation plays a key role in resolving pain

“Neutrophils dominate the early stages of inflammation and set the stage for repair of tissue damage. Inflammation occurs for a reason, and it looks like it’s dangerous to interfere with it,” says Professor Mogil, who is also a member of the Alan Edwards Centre for Research on Pain along with Professor Diatchenko.

Experimentally blocking neutrophils in mice prolonged the pain up to ten times the normal duration. Treating the pain with anti-inflammatory drugs and steroids like dexamethasone and diclofenac also produced the same result, although they were effective against pain early on.

Thesefindings are also supported by a separate analysis of 500,000 people in the United Kingdom that showed that those taking anti-inflammatory drugs to treat their pain were more likely to have pain two to ten years later, an effect not seen in people taking acetaminophen or anti-depressants.

Reconsidering standard medical treatment of acute pain

“Our findings suggest it may be time to reconsider the way we treat acute pain. Luckily pain can be killed in other ways that don’t involve interfering with inflammation,” says Massimo Allegri, a Physician at the Policlinico of Monza Hospital in Italy and Ensemble Hospitalier de la Cote in Switzerland.

“We discovered that pain resolution is actually an active biological process,” says Professor Diatchenko. These findings should be followed up by clinical trials directly comparing anti-inflammatory drugs to other pain killers that relieve aches and pains but don’t disrupt inflammation.”

Gut microbiome composition predictive of patient response to statins

Statins may slow progression of MS


More than 40 million Americans take statins, the most common type of prescription drug. While statins have been shown to effectively lower cholesterol levels and reduce the risks of stroke and heart attack, they do not work the same for everyone, and side effects of statin use include an increased risk of developing type 2 diabetes.

Researchers from Institute for Systems Biology have shown that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published today in the journal Med, and offer promising avenues for optimizing precision statin treatments for individual patients. 

The research team found that the composition and diversity of the gut microbiome is predictive of the efficacy of statins and the magnitude of negative side effects. 

“Specifically, we found that a Bacteroides enriched microbiome with lower levels of diversity was associated with the strongest LDL-lowering response to statins, but also coincided with the greatest disruption to blood glucose levels,” said Dr. Tomasz Wilmanski, lead author of the study. 

The team also found that individuals with a Ruminococcaceae enriched microbiome were protected from the negative side effects of statins on insulin resistance while also showing a clear LDL-lowering response. 

Wimanski and his colleagues built statistical models with microbiome, metabolome, human genome, and clinical records from an American cohort of more than 1,800 people and made their initial discoveries about variable statin effects on both cholesterol and blood glucose markers. Next, they validated their results in an independent European cohort of nearly 1,000 people.  

The unique combination of microbiome and genomic information in this study provides exciting new insights into potential approaches to precision drug treatments. 

The genetic fingerprint of a patient, which includes known genetic markers of statin treatment response, has already been leveraged in the clinic to guide personalized statin treatment regimes. In this study, the authors found that the variability in statin responses explained by the microbiome were completely independent of the variability captured by the genome. “It’s a completely different axis of variability, so we’re able to build models including both genetics and the gut microbiome to improve our statin response predictions,” Wilmanski said. “The genome and the microbiome, together, appear to provide a more comprehensive and complementary picture of personalized drug responses.” 

A logical follow-up to this work is a clinical trial. “It would be great to take this knowledge about the genome and the microbiome and predict personalized dosing regimens for a cohort of patients, and then follow these patients forward in time, tracking their metabolic health and their LDL cholesterol levels, to show that this population of patients undergoing a precision intervention do better than a control group of patients who are getting what is normally prescribed,” said ISB Assistant Professor Dr. Sean Gibbons, a corresponding author on the paper. 

‘Control sugar levels sooner to guard against heart attacks’ finds new study into type 2 diabetes


The study from Surrey suggests that controlling blood sugar levels within the first year of diagnosis reduces the incidence of major cardiovascular events. Furthermore, the team also found that the more a patient’s blood levels varied 12-months after diagnosis, the more likely they were to experience dangerous cardiovascular events. 

Dr Martin Whyte, co-author of the study and Reader in Metabolic Medicine at the University of Surrey, said: 

“The conventional wisdom has been to slowly and steadily treat type 2 diabetes with diet and medicine dose-escalation over years – the period over which it took people to reduce their sugar levels after diagnosis was thought less important for major vascular protection. However, our observational study suggests that getting blood levels under control quickly – within the first 12 months after diagnosis – will significantly help reduce cardiovascular events.”  

Type 2 diabetes is a common condition that results in the level of sugar in the blood becoming too high. The condition is linked to obesity or a family history of type 2 diabetes and can increase a person’s risk of getting serious health conditions.  

The University of Surrey’s study used Royal College of General Practitioners’ Research and Surveillance Centre database to perform a comprehensive examination of glycaemic control achieved within the first year of diagnosis and subsequent blood sugar level variability with cardiovascular disease incidents. 

Music Therapy and its Impact on the Brain

Music Therapy and its Impact on the Brain | Elizabeth Stegemöller |  TEDxIowaStateUniversity - YouTube


Elizabeth Stegemöller presents at the TEDx IowaStateUniversity event on music therapy and its impact on the brain. She is a music therapist and utilizes music therapy to treat people with Parkinson’s disease. Ms Elizabeth Stegemöller is an assistant professor at Iowa State University in the Department of Kinesiology and is known nationally as the neuroscience expert in music therapy. Stegemöller is also an advocate for furthering research into Parkinson’s disease.

How your immune system is fighting for you.

How your immune system is fighting for you. | Julia Jellusova | TEDxFreiburg  - YouTube


Did you know that we live in a dangerous world? We are surrounded by viruses and bacteria and the only reason why we survive is our immune system! In her humorous talk Julia Jellusova, a biologist focusing on immunology, explains the role of B-cells and what toymaking has to do with our immune system. Using interesting examples, she explains the importance of further research on B-cells and how our body can even fight cancer. Julia Jellusova is a scientist in one of the University of Freiburg’s new Excellence Clusters: CIBSS – the Centre for Integrative Biological Signalling Studies. Her research group focuses on how the metabolism of immune cells controls their function and their ability to fight infection and cancer. She also explores how defects in the immune system can lead to autoimmune diseases.

Julia has a passion for sharing her fascination of the immune system with young scientists and with the public. Aside from her research activities, she is also a writer and illustrator of children’s books, including a recent book entitled ‘Entdecke dein Immunsystem’.